Checkmate 142 Nivolumab & Ipilimumab 55Response Rate in MSI High

Checkmate 142 Nivolumab & Ipilimumab 55Response Rate in MSI High

307 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
Report 0 0
Category:
Description:
Cathy Eng, MD, FACP GASTROINTESTINAL MEDICAL ONCOLOGY - MD Anderson discusses the trial Checkmate 142 Nivolumab & Ipilimumab and how it has shown a 55% Response Rate in MSI High patients. Recorded at ASCO GI 2018.
Up Next Autoplay